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Objective: Investigation of osteoarthritis (OA) risk alleles suggests that reduced levels of growth and
differentiation factor-5 (GDF5) may be a precipitating factor in OA. We hypothesized that intra-articular
recombinant human GDF5 (rhGDF5) supplementation to the OA joint may alter disease progression.
Methods: A rat medial meniscus transection (MMT) joint instability OA model was used. Animals
received either one intra-articular injection, or two or three bi-weekly intra-articular injections of either
30 mg or 100 mg of rhGDF5 beginning on day 21 post surgery after structural pathology had been
established. Nine weeks after MMT surgery, joints were processed for histological analysis following
staining with toluidine blue. Control groups received intra-articular vehicle injections, comprising a
glycine-buffered trehalose solution. OA changes in the joint were evaluated using histopathological end
points that were collected by a pathologist who was blinded to treatment.
Results: Intra-articular rhGDF5 supplementation reduced cartilage lesions on the medial tibial plateau in
a dose-dependent manner when administered therapeutically to intercept OA disease progression. A
single 100 mg rhGDF5 injection on day 21 slowed disease progression at day 63. A similar effect was
achieved with two bi-weekly injections of 30 mg. Two bi-weekly injections of 100 mg or three bi-weekly
injections of 30 mg stopped progression of cartilage lesions. Importantly, three biweekly injections of
100 mg rhGDF5 stimulated signiﬁcant cartilage repair.
Conclusions: Intra-articular rhGDF5 supplementation can prevent and even reverse OA disease pro-
gression in the rat MMT OA model. Collectively, these results support rhGDF5 supplementation as an
intra-articular disease modifying OA therapy.
© 2016 The Author(s). Published by Elsevier Ltd on behalf of Osteoarthritis Research Society
International. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction
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meniscus transection (MMTof the transforming growth factor-b (TGF-b) superfamily1. GDF5 is a
developmental marker for early joint formation in the embryo, and
is involved in the maintenance and repair of bone and cartilage in
the adult2,3. The importance of GDF5 in synovial joint development
is well established2, as is the importance of GDF5 for normal sy-
novial joint function4. Mutations in GDF5 also cause chon-
drodysplasias that prevent normal skeletal development and are
associated with severe articular abnormalities5. Interestingly, sin-
gle nucleotide polymorphisms (SNPs) in the human GDF5 gene
have been identiﬁed by genome-wide association studies (GWAS)
as signiﬁcant genetic risk factors associatedwith osteoarthritis (OA)
by different investigators studying distinct populations of OAesearch Society International. This is an open access article under the CC BY-NC-ND
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untranslated region (UTR) of the GDF5 promoter results in a CeT
transition substitution that was originally identiﬁed in a GWAS
cohort of Asian descent6. The association of this rs143383 SNP with
OA was subsequently replicated in a cohort of European descent7.
On a mechanistic level, the risk associated “T” allele has been
shown to have signiﬁcantly reduced transcriptional activity
compared to the “C” allele in chondrocytes, the resident cells that
are responsible for synthesizing and maintaining cartilage11.
Therefore, the increased OA susceptibility associated with the
rs143383 SNP is believed to be mediated through reduced
expression of GDF511e13.
The therapeutic potential of GDF5 in connective tissue (ﬁbrous
and cartilaginous) healing has been demonstrated in several pre-
clinical model systems. For example, stimulatory effects of exoge-
nous GDF5 on matrix synthesis in human articular chondrocytes
have been demonstrated in vitro using cells harvested from healthy
individuals as well as OA patients14,15. In addition, animal studies
have shown that exogenous GDF5 treatment can stimulate rodent
tendon healing16,17 and can positively impact the degeneration of
intervertebral discs in mouse, rabbit and bovine models18e20.
Collectively, this foundation of evidence supports our hypothesis
that intra-articular supplementation of recombinant human GDF5
(rhGDF5) in an osteoarthritic joint may provide a therapeutic
means to prevent disease progression and potentially activate
anabolic responses leading to cartilage repair. Therefore, we stud-
ied the effect of intra-articular GDF5 supplementation in the rat
medial meniscus transection (MMT) model of progressive degen-
erative OA. A distinct beneﬁt of the MMT model is that it is a well-
established model for studying OA structural changes where the
kinetics of disease progression are highly reproducible21,22. We
found that therapeutic intra-articular supplementation of rhGDF5
beginning on day 21 post MMT surgery slowed disease progression
with a single 100 mg injection, whereas two bi-weekly 100 mg in-
jections arrested disease progression and three bi-weekly 100 mg
injections stimulated cartilage repair. The effects were dose-
dependent, as two bi-weekly 30 mg injections were necessary to
achieve protective effects similar to those observed for a single
100 mg injection, and three bi-weekly 30 mg injections were
necessary to provide levels of disease arrest similar to those
observed with two bi-weekly 100 mg injections. Taken together,
these data support the therapeutic potential of intra-articular
supplementation with rhGDF5 as a disease modifying therapy for
OA.
Materials and methods
rhGDF5 preparation
Bulk rhGDF5 was obtained from Biopharm GmbH at a concen-
tration of 3.5 mg/ml in 10 mM HCl in a frozen format stored
at 80C. The frozen bulk protein was thawed overnight at 2e8C
prior to formulation. Bulk rhGDF5 was dialyzed against a 5 mM
glycine-HCl buffer overnight through a 3000 MW cutoff membrane
at 2e8C. Dialysis resulted in an increase in concentration to
3.8 mg/ml rhGDF5. This rhGDF5 solutionwas then diluted to a ﬁnal
concentration of 0.5 mg/ml rhGDF5 in a 5 mM glycine-HCl buffer
containing 5% trehalose (W:V) at pH 3.0. This solution was then
passed through a 0.22 micron ﬁlter and further diluted with sterile
5 mM glycine-HCl buffer with 5% trehalose at pH 3.0 to obtain
working concentrations for injection. One ml of each formulation
was dispensed directly into vials for lyophilization to achieve the
indicated treatment dosages when the lyophilized cake is resus-
pended in 1 ml of water for injection. Vials from sample lots were
tested at random after reconstitution with water for injection toPlease cite this article in press as: Parrish WR, et al., Intra-articular ther
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dx.doi.org/10.1016/j.joca.2016.11.002conﬁrm concentration, stability, and potency of rhGDF5 prior to
initiation of animal studies using OsteoArthritis Research Society
International (OARSI) recommended methodologies described in
detail elsewhere23, with minor modiﬁcations to enhance the ac-
curacy of themeasurement of collagenmatrix loss (parameter #1 in
the OARSI guidelines). Rather than employing the broad the 0, 50%
and 100% loss scaling outlined by Gerwin, Bendele, Glasson, and
Carlson21, a more sensitive range of loss approachwas used in order
to provide a more speciﬁc and detailed look at the depths of
degeneration and/or repair. This modiﬁcation includes tibial carti-
lage micrometer measurements for minimal damage (superﬁcial,
affecting upper 10% only), mild damage (extending through 11e30%
of the cartilage thickness), moderate damage (extending through
31e60% of the cartilage thickness), marked damage (extending
through 61e90% of the cartilage thickness), severe damage (total or
near total loss of collagen to tidemark, >90% thickness), and any
damage (ﬁbrillation ranging from superﬁcial to full thickness loss).
“Any damage” corresponds to the 0% measure in the OARSI
Guidelines, and “severe damage” corresponds to the 100%measure.
This expanded scaling provides the sensitivity to express the
micrometer measurements either individually or in sum combi-
nations to examine potential effects on cartilage sparing or repair in
a therapeutic setting. None of the un-injected control animals at
day 63 displayed lesions more shallow than the range of “moderate
damage” (31e60% of the cartilage thickness), therefore the analysis
for this parameter was focused on the sum of cartilage degenera-
tion including moderate, marked, and severe damage so that this
parameter indicates beneﬁcial treatment effects on matrix loss
extending through 31% or greater of the cartilage thickness.
Animals
This study was carried out in strict accordance with the stan-
dards set forth by the Animal Welfare Act and the recommenda-
tions in ‘Guide for the Care and Use of Laboratory Animals’ (HHS
Publication (NIH) No. 85-23), The protocol was approved by the
Institutional Animal Care and Use Committee at Bolder BioPATH,
Inc (Protocol# BBP-008). All surgery was performed under iso-
ﬂurane anesthesia, and all efforts were made to minimize suffering
with pre and post-operative analgesia. Male Lewis rats weighing
approximately 300 g (~12 weeks upon arrival) (Charles River,
Wilmington, MA) were housed three per cage in shoe-box poly-
carbonate cages with wire tops in sanitary ventilated animal rooms
with temperatures ranging between 67 and 76 F and relative hu-
midity between 30 and 70%. Automatic timers provided 12 h of
light and 12 h of dark. Cages contained wood chip bedding and
suspended food (Rodent chow, Harlan Teklad, Indianapolis, IN) and
access to water bottles ad libitum. Animals were acclimated for 7
days prior to being randomized into groups. An attending veteri-
narian was on site or on call during the live phase of the study.
Induction of OA
Animals were anesthetized with isoﬂurane and the right knee
area was shaved and scrubbed in preparation for surgery. A skin
incision was made over the medial aspect of the knee and the
medial collateral ligament (MCL) was exposed by blunt dissection,
and then transected. Themedial meniscus was reﬂectedmedially to
prevent damage to the articular cartilage, then cut through its full
thickness with small surgical scissors to simulate a complete
meniscal tear. Skin and subcutis were closed with 4-0 VICRYL™
suture. All animals resumed weight bearing immediately post-
surgery upon recovery from anesthesia and there was no evi-
dence of excessive post-operative swelling indicative of joint
infection.apy with recombinant human GDF5 arrests disease progression and
) model of osteoarthritis, Osteoarthritis and Cartilage (2016), http://
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For all injected treatment groups (n ¼ 15), sterile solutions of
rhGDF5 or vehicle were delivered directly to the synovial ﬂuid of
the knee via intra-articular injection. Injections were carried out
using 500 ml insulin syringes with 28 1/200 needles. In every case,
dosing was conducted in a 50 ml volume according to the assigned
regimen as detailed in the study schematic shown in Table I. The
study design included low (30 mg) and high (100 mg) dose treat-
ments that have been shown to protect cartilage in the MMTmodel
in rats when administered each week for 5 weeks24. In the current
study, doses were administered in an exposure de-escalation
format as either a single injection, or two or three bi-weekly in-
jections in order to study the durability of rhGDF5 effects (single
injection at week 3) as well as the effects of repeat dosing at week 5
and at weeks 5 and 7 in the rat knee joint following OA disease
establishment. For each dosing regimen, rhGDF5 vehicle control
groups were included. An unun-injected (no treatment or un-
treated), MMT surgery group terminated at 3 weeks post MMT
surgery was also included to determine the extent of OA patho-
logical changes within the knee at the time when interventions
were initiated. All treatment groups were bench marked against an
unun-injected (no treatment or untreated) group that received
MMT surgery and no further intervention. The veterinarian, sur-
geon, histopathologist, and technical staff were blinded to the
therapy assigned to each randomized group.
Histopathology
Histopathological assessments were carried out in a blinded,
unbiased fashion, essentially as described21. Brieﬂy, the knee joints
with patellae removed were ﬁxed in 10% NBF for 3 days. Joints were
then decalciﬁed in Surgipath decalciﬁer I (Grayslake, IL) for
approximately 1 week. When decalciﬁcation was complete, the
knees were transected in the frontal plane at the level of the
anterior cruciate ligament so the medial and lateral orientationwas
maintained and both halves were embedded in parafﬁn with the
cut side on the face of the block. Three sections were cut from each
knee at approximately 200 mm intervals. Sectioning in this manner
provides simultaneous histological coverage of the anterior and
posterior aspects of the central tibial plateau and the corresponding
articulation of the femoral condyle across the weight bearing re-
gion where the most severe osteoarthritic lesions develop in this
model21. The sections were stained with toluidine blue and pho-
tomicrographs were taken using a CoolSNAP™-Pro microscope
camera. The three most severely affected sections from either the
anterior or posterior side of the joint were evaluated for cartilageTable I
Group assignments and treatment schedule
Group# Treatment D ¼ 0 D ¼ 7 D ¼ 14 D ¼ 21
1 Untreated Sx sac
2 Untreated Sx ANX
3 V 3X Sx X
4 30 3X Sx X
5 100 3X Sx X
6 100 2X Sx X
7 30 2X Sx X
8 V 2X Sx X
9 100 1X Sx X
10 V 1X Sx X
11 30 1X Sx X
V ¼ vehicle treated; Sx ¼ surgery; Anx ¼ anesthesia without intervention; X ¼ injection
Animals were randomly assigned to groups, and groups were then randomly assigned to
anesthesia, and all groups were subjected to anesthesia at each intervention point regar
groups. Veterinary and histopathology staff was blinded with respect to treatment.
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values for each parameter represent the average across the three
sections analyzed per knee joint. Parameters considered were
severe þ marked þ moderate matrix degeneration width, signiﬁ-
cant tibial cartilage degeneration width, zone 2 lesion depth ratio,
medial tibial osteophyte width, and MCL thickness.
Statistics
Statistical analysis of histopathology parameters was done by
comparing group values using the Student's two-tailed t-test with
signiﬁcance set at P < 0.05. This analysis was performed for each
treatment paradigm compared to its corresponding vehicle control
group, as well as, for each treatment or vehicle group compared to
the un-injected controls (day 21 un-injected, day 63 un-injected).
Results
Intra-articular supplementation with rhGDF5 prevented and
reversed OA pathology in a dose and administration regimen
dependent manner
Photomicrographs taken from the median animal in each group
(n ¼ 15 per group) are shown in Fig. 1 relative to vehicle and un-
injected controls. Substantial cartilage degeneration on the
medial tibial plateau was apparent by day 21 following MMT sur-
gery (Fig. 1 and Table II), demonstrating the aggressive nature of
OA-like pathology in this model. If left un-injected, OA-like lesions
become progressively larger and deeper by day 63 post MMT, and
ultimately result in complete eburnation of the articular cartilage,
sclerosis of the subchondral bone with formation of bone marrow
lesions, and the duplication and collapse of the calciﬁed cartilage
tidemark21 [Fig. 1(b)]. The glycine-buffered trehalose vehicle did
provide some limited protection to the cartilage in this model
compared with the day 63 un-injected group [Fig. 1(c), Table II and
Supplemental Tables 1e4]. These beneﬁcial effects were more
evident for the multiple injection vehicle groups where differences
in histological parameters were statistically signiﬁcant compared
with day 63 un-injected controls (Supplemental Tables 1e4).
However, substantial improvements in the architecture of the
cartilage were apparent only for the rhGDF5 treated groups, and
were especially evident upon repeat injection [Fig. 1(d)e(f) and
Table II]. Indeed, the three 100 mg rhGDF5 injection group clearly
demonstrated reparative changes in the joint tissues resulting in
thickening of the femoral cartilage and signiﬁcant repair of the
medial tibial cartilage [Fig. 1(g), Table II and Supplemental
Tables 1e4]. Quantitative analysis of histopathological changesD ¼ 28 D ¼ 35 D ¼ 42 D ¼ 49 D ¼ 56 D ¼ 63
ANX ANX sac
X X sac
X X sac
X X sac
X ANX sac
X ANX sac
X ANX sac
ANX ANX sac
ANX ANX sac
ANX ANX sac
as indicated per group assignment; sac ¼ termination.
treatment regimens. Intra-articular injections were administered under isoﬂurane
dless of their treatment group in order to maintain congruency in handling across
apy with recombinant human GDF5 arrests disease progression and
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Fig. 1. Representative toluidine blue stained micrographs display histopathological changes present in the medial tibio-femoral joint from each group relative to un-injected and
vehicle controls. Note the progressive improvement in cartilage architecture between the single injection and the three injection regimens. a) no intervention at day 21 post MMT,
b) no intervention at day 63 post MMT, c) three bi-weekly vehicle injections, d) three biweekly 30 mg GDF5 injections, e) two bi-weekly 30 mg GDF5 injections, f) single 30 mg GDF5
injection, g) three bi-weekly 100 mg GDF5 injections, h) two bi-weekly 100 mg GDF5 injections, i) single 100 mg GDF5 injection. 50 original magniﬁcation.
Table II
Summary of histopathological measurements and observations
Treatment
group
Matrix degeneration
width (severe þ marked þ
moderate) (microns)
Substantial tibial
cartilage degeneration
width (microns)
Zone 2 lesion
depth ratio
Medial tibial
osteophyte size
(microns)
MCL thickness
(microns)
Day 63 No treatment 513.3 (59.1) 788.9 (38.2) 0.42 (.02) 636.9 (50.4) 611.6 (35.9)
1 injection Vehicle 453.3 (111.5) 773.3 (73.1) 0.43 (0.05) 607.3 (44.6) 604.4 (25.7)
30 mg 364.4 (104.1) 674.4 (99.7) 0.34 (0.07) 631.3 (49.3) 732.4 (39.1)
100 mg 173.3 (89.5) 623.3 (67.8) 0.29 (0.06) 722.2 (72.5) 922.7 (71.0)
2 injection Vehicle 360.3 (89.4) 695.6 (62.3) 0.36 (0.06) 573.6 (61.7) 616.0 (17.1)
30 mg 223.3 (96.2) 573.3 (102.4) 0.31 (0.04) 658.2 (56.1) 799.1 (28.6)
100 mg 149.4 (88.1) 501.1 (86.8) 0.25 (0.03) 872.2 (90.7) 989.3 (75.4)
3 injection Vehicle 437.7 (118.6) 681.1 (85.8) 0.37 (0.05) 579.8 (70.6) 644.4 (27.4)
30 mg 212.2 (123.2) 498.9 (133.3) 0.27 (0.07) 696.7 (69.8) 881.8 (45.0)
100 mg 45.2 (27.0) 389.3 (89.4) 0.18 (0.04) 881.0 (111.6) 1213.3 (93.2)
Day 21 No treatment 120 (61.7) 562.2 (119.8) 0.33 (0.05) 450.2 (27.1) 521.8 (18.2)
Values represent the groupmean (n¼ 15) and the 95% conﬁdence interval in parentheses. Note thatMatrix degeneration width corresponds with OARSI scoring parameter #1,
Substantial tibial cartilage degeneration width corresponds with parameter #4, Zone 2 lesion depth ratio corresponds with parameter #5, medial tibial osteophyte size
corresponds with parameter #6, and MCL thickness corresponds with parameter #921.
W.R. Parrish et al. / Osteoarthritis and Cartilage xxx (2016) 1e74following intra-articular supplementation with rhGDF5 on OA
progression in rats subjected to MMT is displayed in Table II. These
measures included the width of substantial tibial cartilage lesions
involving greater than 50% of the normal cartilage thickness (Fig. 2
and Supplemental Table 1), the width of tibial cartilage matrix
degeneration (Fig. 3 and Supplemental Table 2), and the depth of
cartilage lesions in zone 2, the central zone, of the medial tibial
plateau (Fig. 4 and Supplemental Table 3). Substantial anabolic ef-
fects on the thickness of the MCL and on medial osteophyte
development were also observed (Figs. 5 and 6, Table I and
Supplemental Table 4). However, different treatment regimensPlease cite this article in press as: Parrish WR, et al., Intra-articular ther
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dx.doi.org/10.1016/j.joca.2016.11.002differed greatly in their capacity to stimulate anabolic changes in
the MCL and especially in osteophyte growth (Fig. 6 and Table II).
For example, Fig. 6 shows that signiﬁcant osteophyte enhancement
was not evident in the 30 mg rhGDF5 injection groups compared to
Day 63 un-injected controls, however each of these groups dis-
played an increase in the thickness of the repaired MCL (Fig. 6). In
contrast, multiple injections of 100 mg rhGDF5 did cause signiﬁcant
enhancement of osteophyte growth compared to Day 63 un-
injected controls (Fig. 6). A single 100 mg rhGDF5 injection did
not signiﬁcantly affect osteophyte growth, however signiﬁcantly
enhanced repair of the MCL was evident in each 100 mg rhGDF5apy with recombinant human GDF5 arrests disease progression and
) model of osteoarthritis, Osteoarthritis and Cartilage (2016), http://
Fig. 2. Substantial cartilage degeneration width (OARSI histopathology guideline
parameter #421). The width of tibial cartilage in which 50% or greater of the original
thickness (from surface to tidemark) was seriously compromised was measured
microscopically using a calibrated digital micrometer. Note that the medial tibial
cartilage in the rat is typically about 2000 microns wide across the load bearing area
that was analyzed. A cartilage area is considered to be substantially compromised
when 50% or more of chondrocytes are absent or necrotic. Graph data represent the
group mean (n ¼ 15) ± S.E.M. Therapeutic beneﬁt encompasses the range of improve-
ment in histology parameters that falls between the values for day 21 and day 63 un-
injected groups. Disease arrest indicates histology parameters that are substantially
equivalent to the day 21 un-injected group where the net effect of therapy is no
progression of cartilage degeneration. Repair deﬁnes the degree of histological
improvement that shows decreased cartilage lesion size compared to the day 21 un-
injected control group.
Fig. 3. Cartilage matrix degeneration width (OARSI histopathology guideline param-
eter #121). The width of tibial cartilage matrix loss was measured microscopically using
a calibrated digital micrometer. This measurement only takes cartilage matrix into
account regardless of cellularity or viability of the tissue. Graph data represent the
group mean (n ¼ 15) ± S.E.M. Therapeutic beneﬁt encompasses the range of improve-
ment in histology parameters that falls between the values for day 21 and day 63 un-
injected groups. Disease arrest indicates histology parameters that are substantially
equivalent to the day 21 un-injected group where the net effect of therapy is no
progression of cartilage degeneration. Repair deﬁnes the degree of histological
improvement that shows decreased cartilage lesion size compared to the day 21 un-
injected control group.
Fig. 4. Zone 2 lesion depth ratio (OARSI histopathology guideline parameter #521). The
lesion depth ratio is calculated by dividing the depth of the lesion by the full thickness
of the cartilage from projected articular surface to tidemark. These measurements are
taken at the midpoint of zone 2 using an ocular micrometer. This parameter can be
used to document cartilage thickening and increased matrix deposition. Graph data
represent the group mean (n ¼ 15) ± S.E.M. Therapeutic beneﬁt encompasses the range
of improvement in histology parameters that falls between the values for day 21 and
day 63 un-injected groups. Disease arrest indicates histology parameters that are
substantially equivalent to the day 21 un-injected group where the net effect of
therapy is no progression of cartilage degeneration. Repair deﬁnes the degree of his-
tological improvement that shows decreased cartilage lesion size compared to the day
21 un-injected control group.
Fig. 5. MCL thickness (OARSI histopathology guideline parameter #921). Thickness of
the MCL is a sensitive measure of soft tissue anabolic activity during the tissue repair
process. This measurement is made by digital micrometer through a non-tangential
area of repair in the tissue section. Graph data represent the group mean
(n ¼ 15) ± S.E.M. Normal growth encompasses the increase in MCL thickness that falls
between the day 21 and day 63 un-injected group values. Anabolic stimulation deﬁnes
the degree of increased MCL thickness that exceeds the day 63 un-injected control
group. Note the MCL thickness in a normal non-surgical condition was 272 ± 8 microns
(data not shown), indicating the normal tissue repair response to surgical injury.
W.R. Parrish et al. / Osteoarthritis and Cartilage xxx (2016) 1e7 5treatment group (Fig. 6). These data illuminate a disparity between
anabolic effects of rhGDF5 on osteophytes and on the MCL.
Interestingly, although there were differences in the anabolic
activity of rhGDF5 with respect to osteophytes and the MCL, thePlease cite this article in press as: Parrish WR, et al., Intra-articular ther
stimulates cartilage repair in the rat medial meniscus transection (MMT
dx.doi.org/10.1016/j.joca.2016.11.002effects of two injections of 100 mg rhGDF5 were similar to the ef-
fects of three injections of 30 mg rhGDF5 with respect to measures
of cartilage protection. Similar trends were also apparent in the
comparison between one injection of 100 mg rhGDF5 and twoapy with recombinant human GDF5 arrests disease progression and
) model of osteoarthritis, Osteoarthritis and Cartilage (2016), http://
Fig. 6. Differential anabolic effects of rhGDF5 on osteophytes and the MCL. Values for
anabolic effects of rhGDF5 on osteophytes (OARSI histopathology guideline parameter
#621) and the MCL (OARSI histopathology guideline parameter #921) were transformed
to % of Day 63 un-injected control in order to present values on the same axis. Data
indicate that the magnitude of increased osteophyte size and enhanced MCL repair are
not directly correlated. N ¼ 15 animals per group; * indicates P < 0.05 by 2-tailed
Student's t test compared with Day 63 un-injected control group.
W.R. Parrish et al. / Osteoarthritis and Cartilage xxx (2016) 1e76injections of 30 mg rhGDF5 (Figs. 4 and 6 and Table II). Given the
disparity between effects of rhGDF5 on osteophytes vs the MCL,
these data suggest that the observed protective and reparative ef-
fects on cartilage can be attributed directly to activity of rhGDF5 on
cartilage rather than as a secondary effect of increased joint sta-
bility that might result from enlarged osteophytes or MCL hyper-
plasia. Regardless of the absolute mechanism of action, these data
demonstrate the potential of rhGDF5 to alter the natural history of
OA in the rat MMT model.Discussion
Results of this study clearly indicate a dose- and injection
regimen-dependent effect of rhGDF5 intra articular supplementa-
tion on cartilage preservation and repair in the rat MMT model of
OA. The ability of rhGDF5 to halt disease progression when thera-
peutically administered at 100 mg 2 or 30 mg 3 was profound.
However, the ability of rhGDF5 to reverse the OA-like pathology
and stimulate cartilage repair by multiple histology measures in-
dicates its potential as a potent disease modifying agent when
administered to MMT rats in 3  100 mg doses. It remains possible
that bi-weekly administration is not the optimal therapeutic
approach. Therefore, should clinical development of rhGDF5 be
pursued, dosing studies should investigate dose ranges and other
injection schedules in order to further optimize therapeutic
efﬁcacy.
The ability of the 3 injection regimen at 100 mg dosing to
stimulate cartilage repair should not overshadow the observation
that a single injection of 100 mg rhGDF5 at day 21 provided a sig-
niﬁcant durable cartilage protection measured at day 63
(Supplemental Tables 1e3). Durable cartilage protection in the
presence of the instability lesion (medial meniscal tear) that initi-
ated the OA-like disease process clearly indicates that therapeutic
administration of rhGDF5 stimulated anabolic responses that
altered the natural history of OA-like disease progression in the rat
MMT model. This is particularly important since this 100 mg single
injection therapy did not signiﬁcantly increase osteophyte size
compared with the un-injected group (P ¼ 0.07). Of equal impor-
tance, none of the 30 mg rhGDF5 injection regimens signiﬁcantly
increased osteophyte size compared with the un-injected groupPlease cite this article in press as: Parrish WR, et al., Intra-articular ther
stimulates cartilage repair in the rat medial meniscus transection (MMT
dx.doi.org/10.1016/j.joca.2016.11.002(P > 0.18). These data indicate that osteophyte size and cartilage
protection are not associated in these therapy groups, and strongly
suggests that direct stimulation of reparative responses in the
cartilage are responsible for the observed protective effects of
rhGDF5 supplementation. Regardless of the absolute mechanism of
action, the results of this study clearly demonstrate the disease
modifying potential of intra-articular rhGDF5 supplementation and
its ability to drive cartilage repair in the rat MMT model.
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